Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

Inclusion Criteria: * Age 18 and \<81 years * Active COVID-19 defined as symptoms + SARS CoV-2 identified from upper or lower airway samples * Fever ≥38.5C, admitted to a study hospital, hypoxemia defined as having a peripheral oxygen saturation below 93% (measured by pulse oximetry) and a breathing rate of \>20 breaths per minute without supplemental oxygen treatment * A negative pregnancy test taken before inclusion and use of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential * Written informed consent after meeting with a study physician and ability and willingness to complete follow up. Exclusion Criteria: * No matching plasma donor (exact matching in both the ABO system and the Rh system is required) * Unavailability of plasma * Significant growth of alternative lower airway pathogen such as Streptococcus pneumoniae or Haemophilus influenzae in sputum * Disease duration \>8 Days * Estimated glomerular filtration rate \<60 (kidney failure stage III or more) * Pregnancy (urinary-hcg), breast feeding, * History of severe allergic reactions * Inability to give informed consent * Significantly compromised immunity.\* * Compromised immunity includes but is not limited to treatment with major immunosuppressive agents including high dose corticosteroids, anti-tumor necrosis factor (TNF) agents, calcineurin inhibitors, mTOR inhibitors, lymphocyte depleting biological agents, chemotherapeutic anti neoplastic agents. Also patients with advanced HIV/AIDS, severe immunodeficiency such as hypoglobulinemia, decompensated liver cirrhosis and bone marrow transplant the last year will be excluded.